Alaxia is a leading French biotech firm founded in 2008, dedicated to pioneering therapeutic advancements in respiratory health through its innovative antimicrobial solutions. The company specializes in creating therapeutic solutions for respiratory illnesses with a focus on cystic fibrosis using its unique peroxidase platform. Their flagship drug candidate, ALX-009, is designed to target even the most resilient bacterial strains associated with cystic fibrosis, offering a promising treatment option for this challenging condition.
There is no investment information
No recent news or press coverage available for Alaxia.